Invitrogen Sues Bio-Rad for Allegedly Infringing Certain Protein Gel Patents | GenomeWeb

While a number of companies are competing for proteomics researchers' favor on big-ticket items like mass spectrometers, other firms are vying for market share for lower-end equipment common to every lab doing protein research.

One such market is the protein gel electrophoresis space. To help ensure that it continues to grow its presence in this market, Invitrogen earlier this month sued Bio-Rad Laboratories over this technology, claiming that some of Bio-Rad's protein gels infringe upon certain Invitrogen patents.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.